OBJECTIVES : To define the neuropsychiatric features of amnestic-type Mild Cognitive Impairment (aMCI) and compare them with those of mild Alzheimer's disease (AD). METHODS : The study participants included 353 aMCI and 500 mild AD patients. The Neuropsychiatric Inventory (NPI) was used to assess the neuropsychiatric symptoms in two groups. RESULTS : 65.4% of aMCI and 85.4% of mild AD patients exhibited neuropsychiatric symptoms. The most common symptoms in the aMCI group were depression (33.7%), irritability (29.5%), sleep/ night-time behavior (23.2%), apathy (21.5%), and anxiety (21.2). The most common features in the mild AD group were depression (52.4%), apathy (52%), irritability (41.6%), and anxiety (41%). There were significant differences between the aMCI and mild AD groups in 11 NPI symptoms except sleep/night-time behavior. CONCLUSION : A high prevalence of neuropsychiatric symptoms were associated with aMCI, especially mood disturbances and apathy. In contrast, psychotic symptoms were rare. The neuropsychiatric symptoms observed in aMCI were similar to those of mild AD.
Alzheimer Disease ; Anxiety ; Apathy ; Depression ; Humans ; Mild Cognitive Impairment ; Prevalence

OBJECTIVES : To define the neuropsychiatric features of amnestic-type Mild Cognitive Impairment (aMCI) and compare them with those of mild Alzheimer's disease (AD). METHODS : The study participants included 353 aMCI and 500 mild AD patients. The Neuropsychiatric Inventory (NPI) was used to assess the neuropsychiatric symptoms in two groups. RESULTS : 65.4% of aMCI and 85.4% of mild AD patients exhibited neuropsychiatric symptoms. The most common symptoms in the aMCI group were depression (33.7%), irritability (29.5%), sleep/ night-time behavior (23.2%), apathy (21.5%), and anxiety (21.2). The most common features in the mild AD group were depression (52.4%), apathy (52%), irritability (41.6%), and anxiety (41%). There were significant differences between the aMCI and mild AD groups in 11 NPI symptoms except sleep/night-time behavior. CONCLUSION : A high prevalence of neuropsychiatric symptoms were associated with aMCI, especially mood disturbances and apathy. In contrast, psychotic symptoms were rare. The neuropsychiatric symptoms observed in aMCI were similar to those of mild AD.
Alzheimer Disease ; Anxiety ; Apathy ; Depression ; Humans ; Mild Cognitive Impairment ; Prevalence

OBJECTIVES: The purpose of this study was to examine the determinants of care burden of caregivers in patients with dementia. METHODS: 128 dementia patients and patients' caregivers participated in this study. Care burden using the BI ; cognition using the K-MMSE ; dementia severity using the CDR ; activities of daily living using the S-ADL and the S-IADL ; behaviour problems using NPI were measured. RESULTS: The results showed that care burden was related significantly with the K-MMSE, the CDR, the S-ADL, the SIADL and the NPI total score. Of the behavior problems, agitation/aggression, anxiety, disinhibition, irritability, and aberrant behavior correlated positively with care burden of caregivers. Regression analysis indicated that agitation/aggression, anxiety, the CDR contributed to care burden. CONCLUSION: Agitation/aggression, anxiety and dementia severity contributed to care burden of caregivers. The identified determinants of care burden and the stress of caregivers suggest areas of therapeutic intervention to reduce caregiver's burden so that the institutionalization can be delayed.
Activities of Daily Living ; Anxiety ; Caregivers* ; Cognition ; Dementia* ; Humans ; Institutionalization

OBJECTIVES: Our study investigated the behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease (AD) patients with three groups (mild, moderate, severe) and prevalence of BPSD with the severity of AD. METHOD: In a study group of 338 patients with AD (mild:184, moderate:99, severe:55), information on gender, age, education was collected. The severity of dementia was measured by the Korean version of mini-mental status examination (K-MMSE) and Clinical dementia rating (CDR). The Korean version of Neruopsychiatric Inventory (K-NPI) was administered to all patients. RESULTS: Depression/dysphoria, apathy/indifference, irritability/lability, anxiety were frequent in the mild AD group. Apathy/indifference, Depression/dysphoria, agitation/aggression, delusion were frequent in the moderate AD group. Apathy/indifference, agitation/aggression, aberrant motor behavior, nighttime behavior, anxiety were frequent in the severe AD group. CONCLUSION: These observations suggest that delusion was a more dominant symptom in moderate AD group and the prevalence of depression declined in severe AD group.
Alzheimer Disease ; Anxiety ; Delusions ; Dementia ; Deoxycytidine ; Depression ; Humans ; Prevalence

OBJECTIVES: Clinical utility of the Short Form of the Samsung Dementia Questionnaire (S-SDQ) as a screening instrument for Mild Cognitive Impairment (MCI). METHODS: Three groups (n=27, Subjective Memory Impairment (SMI); n=41 MCI; n=79, Early Alzheimer's Disease(AD)) recruited from memory clinic were administered a battery of neuropsychological tests including S-SDQ and Korean version-Mini Mental State Examination (K-MMSE). RESULTS: S-SDQ, unlike the K-MMSE, had no association with the age and education of the subjects. Scores of S-SDQ was found to correlate (r=-.496) with scores of K-MMSE. Result of Receiver Operating Characteristic (ROC) analysis revealed that S-SDQ discriminated between the SMI and the MCI groups. CONCLUSION: S-SDQ may be a solution to the problem of contamination by education and age which affect traditional cognitive screening instruments like K-MMSE, and it may be a useful tool for screening MCI.
Dementia* ; Education ; Mass Screening ; Memory ; Mild Cognitive Impairment* ; Neuropsychological Tests ; Surveys and Questionnaires* ; ROC Curve

This study was conducted to examine the reliability, validity and clinical utility of the Severe Impairment Battery (SIB) for a Korean population. 69 dementia patients with Clinical Dementia Rating (CDR) stages 2 or 3 were participated in this study. The SIB, Korean version-Mini Mental State Examination (K-MMSE), CDR, and Seoul-Activities of Daily Living (S-ADL) were administered. The validity of the SIB was confirmed by evaluating the correlation coefficients between the SIB and K-MMSE, CDR, S-ADL, which were found to be significant. Cronbach's alpha for the total SIB score and each subscale score showed high significance, and the item-total correlation for each subscale was also acceptable. The test-retest correlation for the total SIB score and subscale scores were significant, except for the praxis and orienting to name. The total SIB score and subscale scores were examined according to CDR. The results suggest that the SIB can differentiate the poor performances of severely impaired dementia patients. On the basis of the receiver operating characteristic (ROC), it can be concluded that the SIB is able to accurately discriminate between CDR 2 and 3 patients. The results of this study suggest that the SIB is a reliable and valid instrument for evaluating severe dementia patients in Korean population.
Severity of Illness Index ; Reproducibility of Results ; ROC Curve ; *Neuropsychological Tests ; Male ; Korea ; Humans ; Female ; Dementia/*diagnosis ; Cognition Disorders/diagnosis ; Cognition ; Aged ; Activities of Daily Living

OBJECTIVE: This study compares the efficacy of the cholinesterase inhibitor (ChEI) galantamine on cognition in patients with mild-to-moderate Alzheimer's dementia (AD) who were either naïve to ChEI drugs or who had failed a trial of the ChEI donepezil. METHODS: Outpatients with AD were sequentially referred for screening and enrollment. Current outpatients who had taken donepezil for at least 6 months without demonstrated efficacy on cognition were switched to galantamine (switched group). New outpatients with no ChEI prescription history were classified as the naïve group and were given galantamine. The primary outcome measures for the between-group comparison were response rate on cognition at 26 and 52 weeks (categorical) and change on the Korean version of the Alzheimer's Disease Assessment Scale-cognitive subscale (dimensional). Secondary cognitive outcomes were measured using the subset of frontal executive function and the Korean Mini-Mental State Examination. RESULTS: Seventy outpatients were enrolled and 66 were analyzed by Intent-to-treat (ITT). There were 42 cases in the naïve group and 24 in the switched group. Response rates did not differ at 26 weeks (71.4% naïve vs. 58.3% switched; p=0.277) or at 52 weeks (59.5% naïve vs. 41.6% switched; p=0.162). No significant differences were observed in the pattern of change over the 52 weeks on the primary and secondary cognitive scales. CONCLUSION: As the efficacy of galantamine on cognition was not inferior in the switched group compared to that in the naïve group, switching ChEI drugs is clinically feasible for non-responding patients with mild-to-moderate AD.
Alzheimer Disease ; Cholinesterases ; Cognition* ; Dementia* ; Executive Function ; Galantamine* ; Humans ; Mass Screening ; Outcome Assessment (Health Care) ; Outpatients ; Prescriptions ; Weights and Measures

OBJECTIVE: Biological markers for Alzheimer's disease (AD) will help clinicians make objective diagnoses early during the course of dementia. Previous studies have suggested that cell cycle dysregulation begins earlier than the onset of clinical manifestations in AD. METHODS: We examined the lymphocyte expression of cell cycle proteins in AD patients, dementia controls (DC), and normal controls (NC). One-hundred seventeen subjects (36 AD, 31 DC, and 50 NC) were recruited. The cell cycle proteins CDK2, CDK4, CDK6, cyclin B, and cyclin D were measured in peripheral lymphocytes. Cell cycle protein expression in the three groups was compared after adjusting for age and sex. RESULTS: The levels of cell cycle proteins CDK2, CDK4, CDK6, cyclin B, and cyclin D were significantly higher in AD patients than in the NC subjects. The DC group manifested intermediate levels of cell cycle proteins compared with the AD patients and the NC subjects. The present study indicates that cell cycle proteins are upregulated in the peripheral lymphocytes of AD patients. CONCLUSION: Cell cycle dysregulation in peripheral lymphocytes may present a promising starting point for identifying peripheral biomarkers of AD.
Alzheimer Disease* ; Biomarkers ; Cell Cycle Proteins* ; Cell Cycle* ; Cyclin B ; Cyclin D ; Cyclins ; Dementia ; Diagnosis ; Humans ; Lymphocytes*

OBJECTIVES: The purpose of this study was to compare the efficacy of donepezil treatment between patients with pure Alzheimer's disease (AD) and Mixed dementia (MD) during a 12-month trial. METHODS: A total of 139 patients were recruited for this 52-week study. The effect of donepezil on cognitive function was measured using Alzheimer's Disease Assessment Scale-cognitive subscale-preliminary Korean version (ADAS-cog-K). Patients' activities of daily living using the Seoul-Instrumental Activities of Daily Living (S-IADL) and Seoul-Activities of Daily Living (S-ADL);behavioral symptoms using the Korean version Neuropsychiatric Inventory (K-NPI) were measured at baseline, 13-weeks, 26-weeks, 39-weeks and 52-weeks. We defined the responsive patients to donepezil at those who showed a cognitive improvement or no change during the first six-month clinical trial. RESULTS: 84 pure AD patients and 34 MD patients were available for intent-to-treat (ITT) last observation carried forward (LOCF) analysis. There was no significant difference between two groups in mean change from baseline in the total ADAS-cog-k, S-ADL, S-IADL and K-NPI scores at 52-week. Based on the operational criteria, 60.7% of pure AD patients and 58.8% of MD patients were responders to donepezil. CONCLUSION: MD patients had similar levels of efficacy with pure AD patients and donepezil was well tolerated in both groups. These results suggest that donepezil is an effective and well-tolerated treatment for MD patients as well as for pure AD patients.
Activities of Daily Living ; Alzheimer Disease ; Dementia ; Humans ; Indans ; Piperidines

OBJECTIVES: The purpose of this study was to compare the efficacy of donepezil treatment between patients with pure Alzheimer's disease (AD) and Mixed dementia (MD) during a 12-month trial. METHODS: A total of 139 patients were recruited for this 52-week study. The effect of donepezil on cognitive function was measured using Alzheimer's Disease Assessment Scale-cognitive subscale-preliminary Korean version (ADAS-cog-K). Patients' activities of daily living using the Seoul-Instrumental Activities of Daily Living (S-IADL) and Seoul-Activities of Daily Living (S-ADL);behavioral symptoms using the Korean version Neuropsychiatric Inventory (K-NPI) were measured at baseline, 13-weeks, 26-weeks, 39-weeks and 52-weeks. We defined the responsive patients to donepezil at those who showed a cognitive improvement or no change during the first six-month clinical trial. RESULTS: 84 pure AD patients and 34 MD patients were available for intent-to-treat (ITT) last observation carried forward (LOCF) analysis. There was no significant difference between two groups in mean change from baseline in the total ADAS-cog-k, S-ADL, S-IADL and K-NPI scores at 52-week. Based on the operational criteria, 60.7% of pure AD patients and 58.8% of MD patients were responders to donepezil. CONCLUSION: MD patients had similar levels of efficacy with pure AD patients and donepezil was well tolerated in both groups. These results suggest that donepezil is an effective and well-tolerated treatment for MD patients as well as for pure AD patients.
Activities of Daily Living ; Alzheimer Disease ; Dementia ; Humans ; Indans ; Piperidines